Bättre effekt av buprenorfin och metadon vid opiatberoende: Krav på drogfrihet från icke-opioider före behandlingsstart gav resultat

Lakartidningen

Volumn 111, Issue 5, 2014, Pages 147-

  Hoffmann, Orsolya ^a   Frisell, Fredrik ^a   Ljungberg, Tomas ^b  

^a Beroendecentrum psykiatriska kliniken Mälarsjukhuset   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; FEMALE; HUMAN; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; RECURRENT DISEASE; RISK FACTOR; STANDARD; STATISTICS; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84893087552     PISSN: 00237205     EISSN: 16527518     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. J Clin Psychol. 1971;27(4):455-6.
2. Hoffmann O. Opiater och opioider. I: Franck J, Nylander I, redaktörer. Beroendemedicin. Lund: Studentlitteratur; 2011. p. 195-204.
3. Grönbladh L. Heroinberoende. I: Franck J, Nylander I, redaktörer. Beroendemedicin. Lund: Studentlitteratur; 2011. p. 205-18.
4. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
5. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-8.
6. Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641-53.
7. Kreek MJ, Borg L, Ducat E, et al. Pharmacotherapy in the treatment of addicton: methadone. J Addict Dis. 2010;29(2):200-16.
8. Davstad I, Stenbacka M, Leifman A, et al. Patterns of illicit drug use and retention in a methadone program: a longitudinal study. J Opioid Manag. 2007;3(1):27-34.
9. Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75(1):37-45.
10. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797-803.
11. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-58.
12. Öhlin L, Hesse M, Fridell M, et al. Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile. BMC Psychiatry. 2011;11:81.
13. Marsch LA, Stephens MA, Mudric T, et al. Predictors of outcome in LAAM, buprenorphine and methadone treatment for opioid dependence. Exp Clin Psychopharmacol. 2005;13(4):293-302.
14. Socialstyrelsens föreskrifter och allmänna råd om läkemedelsassisterad behandling vid opiatberoende. SOSFS 2009:27.